Drugs and developement: new prospects ahead?
Drugs, International Challenges n° 11, OFDT, 8 p.
The objective of this issue of Drugs, international challenges is to take stock of the relations sustained by drug control and development policies, initially returning to the concept of “alternative development” so as to clarify its intricacies and limitations. A second part explores the emergence of a new conception of the issue, drawing on lessons learned from previous setbacks.
After simply being secondary to eradication policies, alternative development is now envisaged more as an instrument of long-term strategies and socioeconomic integration policies adapted to the territories concerned, taking into account all aspects of the rural condition, together with the primary local drivers to illicit cultivation: ranging from access to land, to participation in political life, through viable integration in economic circuits. Although this general approach to drug control policy is still in the early stages, this new focus currently at work and its tentative applications in the field bring the possibility of a development-oriented drug policy to the table, as a legitimate and credible alternative to the strategies followed over the past forty or so years.
Author: Deborah Alimi
Download the PDF file (854 Ko)
Drugs in Europe
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
What do the latest data tell us about drug production and trafficking trends?
These and other questions are explored in the 2021 European Drug Report, our annual overview of the drug situation in Europe.
The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.